Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Acorda Therapeutics (ACOR)

Acorda Therapeutics (ACOR)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 821
  • Shares Outstanding, K 1,242
  • Annual Sales, $ 117,630 K
  • Annual Income, $ -252,850 K
  • 60-Month Beta 1.40
  • Price/Sales 0.01
  • Price/Cash Flow 0.02
  • Price/Book N/A
Trade ACOR with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -203.83
  • Most Recent Earnings $-175.32 on 04/01/24
  • Latest Earnings Date 05/09/24
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.6116 +8.08%
on 04/11/24
14.1100 -95.32%
on 03/15/24
-11.3390 (-94.49%)
since 03/11/24
3-Month
0.6116 +8.08%
on 04/11/24
18.0000 -96.33%
on 01/18/24
-15.6990 (-95.96%)
since 01/11/24
52-Week
0.6116 +8.08%
on 04/11/24
24.1960 -97.27%
on 05/08/23
-10.3390 (-93.99%)
since 04/11/23

Most Recent Stories

More News
Acorda: Q3 Earnings Snapshot

Acorda: Q3 Earnings Snapshot

ACOR : 0.6610 (-24.86%)
Acorda: Q2 Earnings Snapshot

Acorda: Q2 Earnings Snapshot

ACOR : 0.6610 (-24.86%)
Acorda: Q1 Earnings Snapshot

Acorda: Q1 Earnings Snapshot

ACOR : 0.6610 (-24.86%)
Global Alzheimer’s Disease Diagnostics & Therapeutics Market Expected to Reach $9.6 Billion by 2027

Palm Beach, FL – May 9, 2023 – FinancialNewsMedia.com News Commentary – Alzheimer’s disease (AD) is a progressive and neurodegenerative disorder that attacks the brain’s nerve cells or neurons,...

IMC.AX : 0.100 (unch)
SILO : 1.9700 (+0.51%)
LLY : 745.95 (-0.64%)
ACOR : 0.6610 (-24.86%)
TRVN : 0.3660 (-8.96%)
IMRN : 2.45 (+1.66%)
Global Alzheimer's Disease Diagnostics & Therapeutics Market Expected to Reach $9.6 Billion by 2027

/PRNewswire/ -- Alzheimer's disease (AD) is a progressive and neurodegenerative disorder that attacks the brain's nerve cells or neurons, which results in loss...

SILO : 1.9700 (+0.51%)
LLY : 745.95 (-0.64%)
ACOR : 0.6610 (-24.86%)
TRVN : 0.3660 (-8.96%)
IMRN : 2.45 (+1.66%)
Acorda Therapeutics and Chance Pharmaceuticals Announce Agreement to Commercialize INBRIJA® in China

Acorda Therapeutics, Inc. (Nasdaq: ACOR) and Hangzhou Chance Pharmaceuticals Co. Ltd. today announced that they have entered into distribution and supply agreements to provide INBRIJA ® in China. INBRIJA...

ACOR : 0.6610 (-24.86%)
Acorda First Quarter 2023 Update: Webcast/Conference Call Scheduled for May 11, 2023

Acorda Therapeutics, Inc. (Nasdaq: ACOR) will host a webcast/conference call in conjunction with its first quarter 2023 update and financial results on Thursday, May 11 at 4:30 p.m. ET.

ACOR : 0.6610 (-24.86%)
Acorda Therapeutics to Present INBRIJA® Data at the American Academy of Neurology Annual Meeting

Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that it will present data on INBRIJA (levodopa inhalation powder) and OFF Periods at the American Academy of Neurology (AAN) Annual Meeting, taking...

ACOR : 0.6610 (-24.86%)
Acorda Launches INBRIJA® TV Commercial for Parkinson’s Awareness Month

Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that it has launched an INBRIJA ® (levodopa inhalation powder) television commercial for Parkinson’s Awareness Month.

ACOR : 0.6610 (-24.86%)
Acorda Therapeutics CEO Ron Cohen, M.D., to Hold Virtual Company Presentation and Q&A

Acorda Therapeutics, Inc. (Nasdaq: ACOR) will hold a virtual, video Q&A with its CEO, Ron Cohen, M.D., on Tuesday, April 4 at 1:00pm ET, 10:00am PT.

ACOR : 0.6610 (-24.86%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is in highly oversold territory. Beware of a trend reversal.

See More Share

Business Summary

Acorda Therapeutics, Inc. is a biotechnology company developing and commercializing neurology therapies for Parkinson's disease, migraine and multiple sclerosis. Acorda has a pipeline of novel neurological therapies addressing a range of disorders, including Parkinson's disease and multiple sclerosis....

See More

Key Turning Points

3rd Resistance Point 1.0419
2nd Resistance Point 0.9459
1st Resistance Point 0.8035
Last Price 0.6610
1st Support Level 0.5651
2nd Support Level 0.4691
3rd Support Level 0.3267

See More

52-Week High 24.1960
Fibonacci 61.8% 15.1868
Fibonacci 50% 12.4038
Fibonacci 38.2% 9.6208
Last Price 0.6610
52-Week Low 0.6116

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar